KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Retained Earnings (2016 - 2025)

BeOne Medicines (ONC) has disclosed Retained Earnings for 11 consecutive years, with -$8.3 billion as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 3.33% to -$8.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.3 billion, a 3.33% increase, with the full-year FY2025 number at -$8.3 billion, up 3.33% from a year prior.
  • Retained Earnings was -$8.3 billion for Q4 2025 at BeOne Medicines, up from -$8.4 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $3.2 million in Q1 2021 to a low of -$8.6 billion in Q4 2024.
  • A 5-year average of -$4.4 billion and a median of -$5.1 billion in 2021 define the central range for Retained Earnings.
  • Biggest YoY gain for Retained Earnings was 148.93% in 2021; the steepest drop was 1045353.46% in 2021.
  • BeOne Medicines' Retained Earnings stood at -$5.1 billion in 2021, then surged by 98.48% to -$77.4 million in 2022, then dropped by 28.45% to -$99.4 million in 2023, then crashed by 8554.78% to -$8.6 billion in 2024, then rose by 3.33% to -$8.3 billion in 2025.
  • Per Business Quant, the three most recent readings for ONC's Retained Earnings are -$8.3 billion (Q4 2025), -$8.4 billion (Q3 2025), and -$113.7 million (Q2 2025).